Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Progression free survival (PFS) in Part I

  Measured over: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months.

• Objective response rate (ORR) in Part II

  Measured over: Time from the date of first treatment administration until disease progression or the introduction of a new treatment, assessed up to 20 months.

Changes Tremor has spotted